Maintenance therapy with subcutaneous immunoglobulin in a patient with immune-mediated neuropathic postural tachycardia syndrome.
J Transl Autoimmun
; 4: 100112, 2021.
Article
in En
| MEDLINE
| ID: mdl-34471867
ABSTRACT
AIMS:
We describe the disease course of a 35-year-old female with an autoimmune mediated neuropathic postural tachycardia syndrome (PoTS), who responded to immunoglobulin therapy and stabilized on maintenance therapy with subcutaneous immunoglobulin (SCIg).METHODS:
We provide longitudinal data of clinical scores, tilt-table results and antibody titers.RESULTS:
Initial treatment with intravenous immunoglobulin caused infusion-related side-effects whereas SCIg was well tolerated and improved clinical symptoms and quality of life. Clinical improvement correlated with the reduction of serum antibody titers 22 months after first infusion.CONCLUSIONS:
These findings suggest that autoimmune-mediated neuropathic PoTS can be treated sufficiently with IVIg whereas SCIg minimizes side-effects.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Aspects:
Patient_preference
Language:
En
Journal:
J Transl Autoimmun
Year:
2021
Document type:
Article
Affiliation country: